ICU Medical
ICUI
156.03
-3.70
-2.32%
ICU Medical
US · ICUI
#2287 by market cap
Listed 1970
156.03
-3.70
-2.32%
Live - 5344 symbols - heartbeat 385s ago
· 2026-10-07 19:54
After-hours
156.03
0.00%
- Market cap
- 3.90B
- P/E (TTM)i
- 131.12
- P/Bi
- 1.81
- EPSi
- 0.03
- Div yieldi
- 0.00%
- 52W posi
- 54%
Reader sentiment
Are you bullish or bearish on ICUI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.30, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -6.33% YoY
Margins
- Gross margin
- 36.84%
- Operating margin
- 4.90%
- Net margin
- 0.03%
Key ratios & quality
- Enterprise valuei
- 4.88B
- Altman Z-Scorei
- 2.30
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.40B | 1.27B | 1.27B | 1.32B | 2.28B | 2.26B | 2.38B | 2.23B |
| Gross profit | 570.03M | 471.86M | 461.50M | 491.49M | 697.76M | 739.87M | 824.78M | 822.04M |
| Selling & admin expenses | 320.00M | 276.98M | 283.95M | 302.58M | 608.35M | 606.69M | 638.76M | 625.21M |
| Research & development | 52.87M | 48.61M | 42.95M | 47.50M | 92.98M | 85.34M | 88.62M | 87.50M |
| Operating profit | 155.55M | 140.53M | 135.57M | 141.28M | -3.57M | 47.84M | 97.41M | 109.33M |
| Pretax profit | 22.37M | 114.71M | 97.49M | 123.19M | -114.41M | -78.30M | -66.01M | 4.36M |
| Tax | -6.42M | 13.67M | 10.62M | 20.05M | -40.12M | -48.64M | 51.68M | 2.44M |
| Net profit | 28.79M | 101.04M | 86.87M | 103.14M | -74.29M | -29.66M | -117.69M | 732.00K |
| Basic EPS | 1 | 5 | 4 | 5 | -3 | -1 | -5 | 0 |
| Diluted EPS | 1.33 | 4.69 | 4.02 | 4.74 | -3.11 | -1.23 | -4.83 | 0.03 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 604.70M | 548.87M | 536.99M | 540.70M | 530.23M | 551.68M |
| Gross profit | 210.11M | 208.06M | 200.88M | 202.99M | 206.23M | 235.05M |
| Selling & admin expenses | 157.23M | 159.39M | 152.77M | 155.81M | 154.57M | 151.92M |
| Research & development | 23.29M | 21.87M | 21.25M | 21.09M | 21.28M | 22.70M |
| Operating profit | 29.59M | 26.81M | 26.86M | 26.09M | 30.38M | 60.43M |
| Pretax profit | -10.91M | 33.68M | -2.51M | -15.90M | -3.98M | 23.14M |
| Tax | 4.57M | 1.18M | -658.00K | -2.65M | -34.71M | 7.07M |
| Net profit | -15.48M | 35.34M | -3.40M | -15.73M | 30.13M | 19.09M |
| Basic EPS | -1 | 1 | 0 | -1 | 1 | 1 |
| Diluted EPS | -0.63 | 1.43 | -0.14 | -0.64 | 1.20 | 0.76 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 927.04M | 882.20M | 920.78M | 1.03B | 1.24B | 1.22B | 1.44B | 1.19B |
| Cash & ST investments | 382.11M | 292.64M | 410.78M | 567.25M | 213.01M | 254.72M | 308.57M | 307.96M |
| Inventory | 311.16M | 337.64M | 314.93M | 290.24M | 696.01M | 709.36M | 584.68M | 615.86M |
| Total assets | 1.59B | 1.69B | 1.76B | 1.88B | 4.52B | 4.38B | 4.20B | 4.05B |
| Total current liabilities | 249.29M | 248.47M | 195.49M | 200.78M | 494.56M | 481.84M | 556.18M | 498.86M |
| Short-term debt | -- | 7.36M | 8.74M | 9.01M | 47.86M | 71.16M | 51.00M | 18.75M |
| Long-term debt | -- | -- | -- | -- | 1.62B | 1.58B | 1.53B | 1.27B |
| Total liabilities | 321,736,000.00 | 315,138,000.00 | 261,426,000.00 | 264,707,000.00 | 2,425,713,000.00 | 2,255,029,000.00 | 2,238,696,000.00 | 1,926,683,000.00 |
| Total equity | 1.26B | 1.38B | 1.50B | 1.62B | 2.09B | 2.12B | 1.97B | 2.12B |
| Retained earnings | 620.75M | 721.78M | 808.65M | 911.79M | 837.50M | 807.85M | 690.16M | 690.89M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.42B | 1.18B | 1.21B | 1.19B | 1.21B | 1.21B |
| Cash & ST investments | 289.70M | 300.03M | 299.73M | 307.96M | 288.33M | 298.30M |
| Inventory | 590.33M | 616.47M | 622.44M | 615.86M | 605.59M | 607.42M |
| Total assets | 4.18B | 4.11B | 4.10B | 4.05B | 4.01B | 3.97B |
| Total current liabilities | 549.02M | 482.78M | 492.90M | 498.86M | 517.90M | 498.36M |
| Short-term debt | 61.29M | -- | -- | 18.75M | 18.75M | 18.75M |
| Long-term debt | 1.49B | 1.34B | 1.31B | 1.27B | 1.26B | 1.21B |
| Total liabilities | 2,196,892,000.00 | 1,991,613,000.00 | 1,975,646,000.00 | 1,926,683,000.00 | 1,901,835,000.00 | 1,819,431,000.00 |
| Total equity | 1.99B | 2.12B | 2.13B | 2.12B | 2.11B | 2.15B |
| Retained earnings | 674.68M | 710.02M | 706.62M | 690.89M | 721.02M | 740.11M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 160.22M | 101.92M | 222.75M | 267.54M | -62.13M | 166.20M | 204.03M | 179.85M |
| Depreciation & amortization | 74.74M | 76.92M | 85.63M | 89.70M | 235.15M | 228.77M | 219.51M | 200.74M |
| Free cash flow | 59.44M | -4.12M | 122.36M | 186.37M | -161.46M | 72.53M | 113.83M | 82.83M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 344.78M | 268.67M | 396.10M | 552.83M | 208.78M | 254.22M | 308.57M | 307.96M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 51.33M | 11.21M | 56.71M | 60.60M | 38.91M | 80.15M |
| Depreciation & amortization | 49.45M | 49.67M | 50.80M | 50.83M | 50.00M | 49.64M |
| Free cash flow | 34.47M | -10.79M | 24.96M | 34.19M | 25.70M | 59.99M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 289.70M | 300.03M | 299.73M | 307.96M | 288.33M | 298.30M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 2.34 | 7.65 | 6.03 | 6.61 | -4.01 | -1.41 | -5.76 | 0.04 |
| ROA %i | 1.87 | 6.16 | 5.03 | 5.66 | -2.32 | -0.67 | -2.74 | 0.02 |
| ROIC %i | 2.38 | 7.04 | 5.74 | 6.31 | -1.14 | 1.19 | -1.13 | 1.88 |
| 5-year avg ROE %i | 6.72 | 7.16 | 6.72 | 6.01 | 3.73 | 2.98 | 0.30 | -0.90 |
| EBIT margin %i | 1.65 | 9.10 | 7.81 | 9.42 | -1.91 | 1.08 | 1.70 | 4.38 |
| FCF / sales %i | 4.25 | -- | 9.63 | 14.16 | -- | 3.21 | 4.78 | 3.71 |
| Current ratioi | 3.72 | 3.55 | 4.71 | 5.13 | 2.50 | 2.53 | 2.59 | 2.39 |
| Quick ratioi | 2.39 | 2.06 | 2.83 | 3.45 | 0.93 | 0.91 | 0.91 | 1.03 |
| Debt / assetsi | 0.00 | 2.14 | 2.96 | 2.40 | 38.41 | 38.91 | 38.68 | 32.89 |
| LT debt / equityi | -- | 2.10 | 2.89 | 2.23 | 80.69 | 76.89 | 80.14 | 61.85 |
| Interest coveragei | 32.56 | 209.94 | 56.62 | 144.57 | -0.62 | 0.24 | 0.38 | 1.05 |
| Revenue CAGR (3Y) %i | 60.02 | 49.44 | -0.56 | -2.03 | 21.66 | 21.13 | 21.86 | -0.72 |
| Net income CAGR (3Y) %i | -13.82 | 17.00 | 8.17 | 53.01 | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | 5.75 | -- | 17.86 | 46.37 | -- | -16.00 | -15.16 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -4.62 | -1.78 | -0.35 | 0.04 | 2.26 | 1.41 |
| ROA %i | -2.21 | -0.88 | -0.18 | 0.02 | 1.13 | 0.74 |
| ROIC %i | -0.53 | 0.97 | 1.70 | 1.88 | 2.64 | 2.12 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 2.70 | 4.84 | 5.40 | 4.38 | 4.54 | 3.84 |
| FCF / sales %i | 5.02 | 2.13 | 2.68 | 3.71 | 3.43 | 6.71 |
| Current ratioi | 2.59 | 2.44 | 2.45 | 2.39 | 2.34 | 2.43 |
| Quick ratioi | 0.90 | 1.08 | 1.05 | 1.03 | 0.99 | 1.04 |
| Debt / assetsi | 38.25 | 33.85 | 33.26 | 32.89 | 33.03 | 32.02 |
| LT debt / equityi | 77.43 | 65.71 | 64.15 | 61.85 | 61.89 | 58.22 |
| Interest coveragei | 0.62 | 1.13 | 1.29 | 1.05 | 1.13 | 1.01 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Consumables is the largest reported line at 52.44% of revenue, across 3 reported segments.
- Infusion Systems follows at 34.26%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Consumables52.44%
Infusion Systems34.26%
Vital Care13.31%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.